Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin effect on erythropoiesis and physical fitness in patients with type 2 diabetes
2017-004889-10Phase 4Terminated
- Sponsor
- University Hospital Tübingen
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin in type 2 diabetes mellitus (T2DM) and hypertension (HTN) (3 arms), sponsored by University Hospital Tübingen. Primary endpoint: Change in blood erythropoietin (EPO) levels. Started Apr 2018; status: terminated.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on 2017-004889-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004889-10.